Abstract

BackgroundMalignant pleural mesothelioma (MPM) is a devastating disease with an overall poor prognosis. Despite the recent advances in targeted molecular therapies, there is a clear and urgent need for the identification of novel mesothelioma targets for the development of highly efficacious therapeutics.Methodology/Principal FindingsIn this study, we report that the expression of Sphingosine Kinase 1 (SphK1) protein was preferentially elevated in MPM tumor tissues (49 epithelioid and 13 sarcomatoid) compared to normal tissue (n = 13). In addition, we also observed significantly elevated levels of SphK1 and SphK2 mRNA and SphK1 protein expression in MPM cell lines such as H2691, H513 and H2461 compared to the non-malignant mesothelial Met5 cells. The underlying mechanism appears to be mediated by SphK1 induced upregulation of select gene transcription programs such as that of CBP/p300 and PCAF, two histone acetyl transferases (HAT), and the down regulation of cell cycle dependent kinase inhibitor genes such as p27Kip1 and p21Cip1. In addition, using immunoprecipitates of anti-acetylated histone antibody from SphK inhibitor, SphK-I2 treated Met5A and H2691 cell lysates, we also showed activation of other cell proliferation related genes, such as Top2A (DNA replication), AKB (chromosome remodeling and mitotic spindle formation), and suppression of p21 CIP1 and p27KIP1. The CDK2, HAT1 and MYST2 were, however, unaffected in the above study. Using SphK inhibitor and specific siRNA targeting either SphK1 or SphK2, we also unequivocally established that SphK1, but not SphK2, promotes H2691 mesothelioma cell proliferation. Using a multi-walled carbon nanotubes induced peritoneal mesothelioma mouse model, we showed that the SphK1−/− null mice exhibited significantly less inflammation and granulamatous nodules compared to their wild type counterparts.Conclusions/SignificanceThe lipid kinase SphK1 plays a positive and essential role in the growth and development of malignant mesothelioma and is therefore a likely therapeutic target.

Highlights

  • Malignant pleural mesothelioma (MPM) is a highly aggressive and invasive neoplasm of the pleura linked with asbestos exposure in a majority of patients [1])

  • Having established a role for Sphingosine Kinase 1 (SphK1) in mesothelioma cell proliferation, we investigated if serum stimulated S1P generation in mesothelioma cells

  • We demonstrate a definitive role for SphK1, but not SphK2, in supporting the proliferation of mesothelioma cells

Read more

Summary

Introduction

Malignant pleural mesothelioma (MPM) is a highly aggressive and invasive neoplasm of the pleura linked with asbestos exposure in a majority of patients [1]). One HDAC inhibitor, suberonylanilide hydroxamic acid (SAHA), marketed as Zolinza (vorinostat) has been approved by US Foods and Drugs Administration (FDA) for the treatment of cutaneous T-cell lymphoma (http://www.cancer.gov/cancertopics/druginfo/fdavorinostat) [4]. It is currently being evaluated in Phase III clinical trials in MPM. We define the functional consequence of the down-regulation of SphK1 on the growth of mesothelioma cells and investigated the potential link between SphK1 and acetylation of H3 and H4 histones on mesothelioma cell proliferation. These studies provide novel insights into SphK1 dependent modulation of histone acetylation through histone acetyltransferases and/or histone deacetylases in regulating mesothelioma cell proliferation

Experimental Procedures
Results
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call